Parkinsonian Syndromes (PDS) with predominant motor dysfunction include progressive supranuclear palsy (PSP), multiple system atrophy (MSA) and corticobasal degeneration (CBD). Current treatment options for PDS are extremely limited due to the less understanding of disease pathophysiology and lack of therapeutic targets. Combining the results of previous studies and our group's previous research, sixty qualified PDS patients would be enrolled to conduct a prospective single-center randomized sham controlled clinical trial to verify the new therapeutic options that can improve symptoms and effectively slow the progression of the disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
60
Noninvasive brain stimulation (NIBS) includes a variety of noninvasive neuromodulation techniques such as transcranial magnetic stimulation (TMS), transcranial direct current stimulation (TDCS), and so on. Theta burst stimulation(TBS) is a new form of excitatory or inhibitory rTMS treatment that is less time-consuming and more effective than traditional rTMS in a single treatment session.
Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
RECRUITINGGroup differences of part 3 of Unified Parkinson Disease Rating Scale (UPDRS) changes
Compare the changes in UPDRS scores from baseline to post- treatment in the three intervention groups (UPDRS part3: range 0\~72, higher score is related to a worse outcome).
Time frame: 6 weeks
Group differences of Progressive Supranuclear Palsy Rating Scale (PSPRS)
Compare the changes in PSPRS scores from baseline to post- treatment in the three intervention groups (psp patients specific).
Time frame: 6 weeks
Group differences of Unified Multiple System Atrophy Rating Scale (UMSARS)
Compare the changes in UMSARS scores from baseline to post- treatment in the three intervention groups (MSA patients specific).
Time frame: 6 weeks
Group differences of Cortical Basal ganglia Functional Scale (CBFS)
Compare the changes in CBFS scores from baseline to post- treatment in the three intervention groups (cbd patients specific).
Time frame: 6 weeks
Group differences of Berg Balance Scale (BBS) changes
Compare the changes in BBS scores from baseline to post-treatment in the three intervention groups (BBS: range 0\~56, higher score is related to a better outcome).
Time frame: 6 weeks
Group differences of Hamilton depression scale-17 (HAMD-17) changes
Compare the changes in HAMD-17 scores from baseline to post-treatment in the three intervention groups (HAMD-17: range 0\~38, higher score is related to a worse outcome).
Time frame: 6 weeks
Group differences of Hamilton Anxiety Scale (HAMA) changes
Compare the changes in HAMA scores from baseline to post-treatment in the three intervention groups (HAMA: range 0\~64, higher score is related to a worse outcome).
Time frame: 6 weeks
Group differences of Mini-mental State Examination (MMSE) changes
Compare the changes in MMSE scores from baseline to post-treatment in the three intervention groups (MMSE: range 0\~30, higher score is related to a better outcome).
Time frame: 6 weeks
Group differences of Montreal Cognitive Assessment (MoCA) changes
Compare the changes in MoCA scores from baseline to post-treatment in the three intervention groups (MoCA: range 0\~30, higher score is related to a better outcome).
Time frame: 6 weeks
Group differences of 39-item Parkinson's Disease Questionnaire (PDQ-39) changes
Compare the changes in PDQ-39 scores from baseline to post-treatment in the three intervention groups (PDQ-39: range 0\~156, higher score is related to a worse outcome).
Time frame: 6 weeks
Group differences of Wexner scores changes
Compare the changes in Wexner scores from baseline to post-treatment in the three intervention groups (Wexner: range 0\~30, higher score is related to a worse outcome).
Time frame: 6 weeks
Group differences of Standardized Swallowing Assessment (SSA) changes
Compare the changes in SSA from baseline to post-treatment in the three intervention groups
Time frame: 6 weeks
Group differences of adverse event
Compare the changes in adverse event in the three intervention groups
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.